Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Strengthening national health research systems in the WHO African Region - progress towards universal health coverage.

Rusakaniko S, Makanga M, Ota MO, Bockarie M, Banda G, Okeibunor J, Mutapi F, Tumusiime P, Nyirenda T, Kirigia JM, Nabyonga-Orem J.

Global Health. 2019 Jul 26;15(1):50. doi: 10.1186/s12992-019-0492-8.

2.

Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines - A phase II, randomised, observer-blind study in Gambian infants.

Odutola A, Ota MOC, Antonio M, Ogundare EO, Saidu Y, Owiafe PK, Worwui A, Idoko OT, Owolabi O, Kampmann B, Greenwood BM, Alderson M, Traskine M, Swinnen K, Verlant V, Dobbelaere K, Borys D.

Vaccine. 2019 May 1;37(19):2586-2599. doi: 10.1016/j.vaccine.2019.03.033. Epub 2019 Apr 8.

3.

Proceedings of the first African Health Forum: effective partnerships and intersectoral collaborations are critical for attainment of Universal Health Coverage in Africa.

Ota MOC, Kirigia DG, Asamoah-Odei E, Drameh-Avognon PS, Olu O, Malecela MN, Cabore JW, Moeti MR.

BMC Proc. 2018 Jul 3;12(Suppl 7):8. doi: 10.1186/s12919-018-0104-2. eCollection 2018.

4.

Four-gene Pan-African Blood Signature Predicts Progression to Tuberculosis.

Suliman S, Thompson E, Sutherland J, Weiner Rd J, Ota MOC, Shankar S, Penn-Nicholson A, Thiel B, Erasmus M, Maertzdorf J, Duffy FJ, Hill PC, Hughes EJ, Stanley K, Downing K, Fisher ML, Valvo J, Parida SK, van der Spuy G, Tromp G, Adetifa IMO, Donkor S, Howe R, Mayanja-Kizza H, Boom WH, Dockrell H, Ottenhoff THM, Hatherill M, Aderem A, Hanekom WA, Scriba TJ, Kaufmann SH, Zak DE, Walzl G; GC6-74 and ACS cohort study groups.

Am J Respir Crit Care Med. 2018 Apr 6. doi: 10.1164/rccm.201711-2340OC. [Epub ahead of print]

5.

Kinetics of antibodies against pneumococcal proteins and their relationship to nasopharyngeal carriage in the first two months of life.

Mendy AL, Agbla SC, Odutola AA, Antonio M, Greenwood BM, Sutherland JS, Ota MOC.

PLoS One. 2017 Oct 5;12(10):e0185824. doi: 10.1371/journal.pone.0185824. eCollection 2017.

6.

Mycobacterium tuberculosis Infection in Close Childhood Contacts of Adults with Pulmonary Tuberculosis is Increased by Secondhand Exposure to Tobacco.

Adetifa IMO, Kendall L, Donkor S, Lugos MD, Hammond AS, Owiafe PK, Ota MOC, Brookes RH, Hill PC.

Am J Trop Med Hyg. 2017 Aug;97(2):429-432. doi: 10.4269/ajtmh.16-0611. Epub 2017 Jul 19.

7.

A population-based national estimate of the prevalence and risk factors associated with hypertension in Rwanda: implications for prevention and control.

Nahimana MR, Nyandwi A, Muhimpundu MA, Olu O, Condo JU, Rusanganwa A, Koama JB, Ngoc CT, Gasherebuka JB, Ota MO, Okeibunor JC.

BMC Public Health. 2017 Jul 10;18(1):2. doi: 10.1186/s12889-017-4536-9. Erratum in: BMC Public Health. 2017 Sep 22;17 (1):736.

8.

Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind study.

Odutola A, Ota MOC, Antonio M, Ogundare EO, Saidu Y, Foster-Nyarko E, Owiafe PK, Ceesay F, Worwui A, Idoko OT, Owolabi O, Bojang A, Jarju S, Drammeh I, Kampmann B, Greenwood BM, Alderson M, Traskine M, Devos N, Schoonbroodt S, Swinnen K, Verlant V, Dobbelaere K, Borys D.

Vaccine. 2017 May 2;35(19):2531-2542. doi: 10.1016/j.vaccine.2017.03.071. Epub 2017 Apr 4.

9.

Association of slow recovery of Mycobacterium africanum-infected patients posttreatment with high content of Persister-Like bacilli in pretreatment sputum.

Tientcheu LD, Bell A, Secka O, Ayorinde A, Otu J, Garton NJ, Sutherland JS, Ota MO, Antonio M, Dockrell HM, Kampmann B, Barer MR.

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S99-S100. doi: 10.1016/j.ijmyco.2016.09.033. Epub 2016 Nov 11.

10.

Acceptance of multiple injectable vaccines in a single immunization visit in The Gambia pre and post introduction of inactivated polio vaccine.

Idoko OT, Hampton LM, Mboizi RB, Agbla SC, Wallace AS, Harris JB, Sowe D, Ehlman DC, Kampmann B, Ota MO, Hyde TB.

Vaccine. 2016 Sep 22;34(41):5034-5039. doi: 10.1016/j.vaccine.2016.07.021. Epub 2016 Aug 25.

PMID:
27570237
11.

Developing the African national health research systems barometer.

Kirigia JM, Ota MO, Senkubuge F, Wiysonge CS, Mayosi BM.

Health Res Policy Syst. 2016 Jul 22;14(1):53. doi: 10.1186/s12961-016-0121-4.

12.

The contribution of the polio eradication initiative to narrowing the gaps in the health workforce in the African Region.

Kamso J, Mvika ES, Ota MO, Okeibunor J, Mkanda P, Mihigo R.

Vaccine. 2016 Oct 10;34(43):5150-5154. doi: 10.1016/j.vaccine.2016.05.061. Epub 2016 Jul 6.

13.

Associations between nasopharyngeal carriage of Group B Streptococcus and other respiratory pathogens during early infancy.

Foster-Nyarko E, Kwambana B, Aderonke O, Ceesay F, Jarju S, Bojang A, McLellan J, Jafali J, Kampmann B, Ota MO, Adetifa I, Antonio M.

BMC Microbiol. 2016 May 27;16:97. doi: 10.1186/s12866-016-0714-7.

14.

Host Immune Responses Differ between M. africanum- and M. tuberculosis-Infected Patients following Standard Anti-tuberculosis Treatment.

Tientcheu LD, Haks MC, Agbla SC, Sutherland JS, Adetifa IM, Donkor S, Quinten E, Daramy M, Antonio M, Kampmann B, Ottenhoff TH, Dockrell HM, Ota MO.

PLoS Negl Trop Dis. 2016 May 18;10(5):e0004701. doi: 10.1371/journal.pntd.0004701. eCollection 2016 May.

15.

Elevated serum 25-hydroxy (OH) vitamin D levels are associated with risk of TB progression in Gambian adults.

Owolabi O, Agbla S, Owiafe P, Donkor S, Togun T, Sillah AK, Ota MO, Sutherland JS.

Tuberculosis (Edinb). 2016 May;98:86-91. doi: 10.1016/j.tube.2016.02.007. Epub 2016 Mar 3.

16.

C-reactive protein, Neopterin and Beta2 microglobulin levels pre and post TB treatment in The Gambia.

Mendy J, Togun T, Owolabi O, Donkor S, Ota MO, Sutherland JS.

BMC Infect Dis. 2016 Mar 8;16:115. doi: 10.1186/s12879-016-1447-9.

17.

Use of lateral flow assays to determine IP-10 and CCL4 levels in pleural effusions and whole blood for TB diagnosis.

Sutherland JS, Mendy J, Gindeh A, Walzl G, Togun T, Owolabi O, Donkor S, Ota MO, Kon Fat ET, Ottenhoff TH, Geluk A, Corstjens PL.

Tuberculosis (Edinb). 2016 Jan;96:31-6. doi: 10.1016/j.tube.2015.10.011. Epub 2015 Nov 14.

PMID:
26786652
18.

A randomized controlled study comparing community based with health facility based direct observation of treatment models on patients' satisfaction and TB treatment outcome in Nigeria.

Adewole OO, Oladele T, Osunkoya AH, Erhabor GE, Adewole TO, Adeola O, Obembe O, Ota MO.

Trans R Soc Trop Med Hyg. 2015 Dec;109(12):783-92. doi: 10.1093/trstmh/trv091.

PMID:
26626341
19.

Readiness of ethics review systems for a changing public health landscape in the WHO African Region.

Motari M, Ota MO, Kirigia JM.

BMC Med Ethics. 2015 Dec 2;16(1):82. doi: 10.1186/s12910-015-0078-9.

20.

Reactogenicity, safety and immunogenicity of a protein-based pneumococcal vaccine in Gambian children aged 2-4 years: A phase II randomized study.

Odutola A, Ota MO, Ogundare EO, Antonio M, Owiafe P, Worwui A, Greenwood B, Alderson M, Traskine M, Verlant V, Dobbelaere K, Borys D.

Hum Vaccin Immunother. 2016;12(2):393-402. doi: 10.1080/21645515.2015.1111496.

21.

National health research systems in the WHO African Region: current status and the way forward.

Kirigia JM, Ota MO, Motari M, Bataringaya JE, Mouhouelo P.

Health Res Policy Syst. 2015 Oct 30;13:61. doi: 10.1186/s12961-015-0054-3.

22.

Risk factors for delay in age-appropriate vaccinations among Gambian children.

Odutola A, Afolabi MO, Ogundare EO, Lowe-Jallow YN, Worwui A, Okebe J, Ota MO.

BMC Health Serv Res. 2015 Aug 28;15:346. doi: 10.1186/s12913-015-1015-9.

23.

Epidemiological and Surveillance Response to Ebola Virus Disease Outbreak in Lofa County, Liberia (March-September, 2014); Lessons Learned.

Kouadio KI, Clement P, Bolongei J, Tamba A, Gasasira AN, Warsame A, Okeibunor JC, Ota MO, Tamba B, Gumede N, Shaba K, Poy A, Salla M, Mihigo R, Nshimirimana D.

PLoS Curr. 2015 May 6;7. pii: ecurrents.outbreaks.9681514e450dc8d19d47e1724d2553a5. doi: 10.1371/currents.outbreaks.9681514e450dc8d19d47e1724d2553a5.

24.

Vaccine associated paralytic poliomyelitis cases from children presenting with acute flaccid paralysis in Uganda.

Nanteza MB, Kisakye A, Ota MO, Gumede N, Bwogi J; Expanded Program on Immunization Laboratory Team - Uganda Virus Research Institute (EPI LAB - UVRI).

J Med Virol. 2015 Dec;87(12):2163-7. doi: 10.1002/jmv.24285. Epub 2015 Jul 16.

PMID:
26058454
25.

Differential transcriptomic and metabolic profiles of M. africanum- and M. tuberculosis-infected patients after, but not before, drug treatment.

Tientcheu LD, Maertzdorf J, Weiner J, Adetifa IM, Mollenkopf HJ, Sutherland JS, Donkor S, Kampmann B, Kaufmann SH, Dockrell HM, Ota MO.

Genes Immun. 2015 Jul-Aug;16(5):347-55. doi: 10.1038/gene.2015.21. Epub 2015 Jun 4.

26.

Increasing the value of health research in the WHO African Region beyond 2015--reflecting on the past, celebrating the present and building the future: a bibliometric analysis.

Uthman OA, Wiysonge CS, Ota MO, Nicol M, Hussey GD, Ndumbe PM, Mayosi BM.

BMJ Open. 2015 Mar 13;5(3):e006340. doi: 10.1136/bmjopen-2014-006340. Review.

27.

Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial.

Idoko OT, Owolabi OA, Owiafe PK, Moris P, Odutola A, Bollaerts A, Ogundare E, Jongert E, Demoitié MA, Ofori-Anyinam O, Ota MO.

Tuberculosis (Edinb). 2014 Dec;94(6):564-78. doi: 10.1016/j.tube.2014.07.001. Epub 2014 Aug 9.

28.

Lessons in participant retention in the course of a randomized controlled clinical trial.

Idoko OT, Owolabi OA, Odutola AA, Ogundare O, Worwui A, Saidu Y, Smith-Sanneh A, Tunkara A, Sey G, Sanyang A, Mendy P, Ota MO.

BMC Res Notes. 2014 Oct 9;7:706. doi: 10.1186/1756-0500-7-706.

29.

Antibodies against Haemophilus influenzae type b in The Gambia: investigating the extent of protection across age groups.

Idoko OT, Roberts E, Cox M, Jafali J, Njie-Jobe J, Mackenzie G, Ota MO, Kampmann B.

Vaccine. 2014 Aug 6;32(36):4620-4. doi: 10.1016/j.vaccine.2014.06.078. Epub 2014 Jun 25.

PMID:
24975810
30.

Digitised audio questionnaire for assessment of informed consent comprehension in a low-literacy African research population: development and psychometric evaluation.

Afolabi MO, Bojang K, D'Alessandro U, Ota MO, Imoukhuede EB, Ravinetto R, Larson HJ, McGrath N, Chandramohan D.

BMJ Open. 2014 Jun 24;4(6):e004817. doi: 10.1136/bmjopen-2014-004817.

31.

Factors affecting immunogenicity of BCG in infants, a study in Malawi, The Gambia and the UK.

Hur YG, Gorak-Stolinska P, Lalor MK, Mvula H, Floyd S, Raynes J, Ben-Smith A, Fitchett JR, Flanagan KL, Burl S, Ota MO, Crampin AC, Smith SG, Dockrell HM.

BMC Infect Dis. 2014 Apr 5;14:184. doi: 10.1186/1471-2334-14-184.

32.

Interferon-gamma treatment kinetics among patients with active pulmonary tuberculosis.

Adewole OO, Ota MO, Erhabor GE, Owiafe P, Oladimeji A, Obaseki D.

Niger Med J. 2013 Nov;54(6):376-81. doi: 10.4103/0300-1652.126287.

33.

Rapid diagnosis of tuberculosis using ex vivo host biomarkers in sputum.

Ota MO, Mendy JF, Donkor S, Togun T, Daramy M, Gomez MP, Chegou NN, Sillah AK, Owolabi O, Kampmann B, Walzl G, Sutherland JS.

Eur Respir J. 2014 Jul;44(1):254-7. doi: 10.1183/09031936.00209913. Epub 2014 Mar 13. No abstract available.

34.

Differences in T-cell responses between Mycobacterium tuberculosis and Mycobacterium africanum-infected patients.

Tientcheu LD, Sutherland JS, de Jong BC, Kampmann B, Jafali J, Adetifa IM, Antonio M, Dockrell HM, Ota MO.

Eur J Immunol. 2014 May;44(5):1387-98. doi: 10.1002/eji.201343956. Epub 2014 Feb 20.

35.

Haematological and biochemical reference values of Gambian infants.

Odutola AA, Afolabi MO, Jafali J, Baldeh I, Owolabi OA, Owiafe P, Bah G, Jaiteh B, Mohammed NI, Donkor SA, Ndure J, Adetifa J, Flanagan KL, Ota MOC.

Trop Med Int Health. 2014 Mar;19(3):275-283. doi: 10.1111/tmi.12245. Epub 2014 Jan 7.

36.

Differential gene expression of activating Fcγ receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity.

Sutherland JS, Loxton AG, Haks MC, Kassa D, Ambrose L, Lee JS, Ran L, van Baarle D, Maertzdorf J, Howe R, Mayanja-Kizza H, Boom WH, Thiel BA, Crampin AC, Hanekom W, Ota MO, Dockrell H, Walzl G, Kaufmann SH, Ottenhoff TH; GCGH Biomarkers for TB consortium.

Clin Microbiol Infect. 2014 Apr;20(4):O230-8. doi: 10.1111/1469-0691.12383. Epub 2013 Nov 11.

37.

Diagnostic utility of QuantiFERON-TB gold in-tube in active pulmonary Tuberculosis in Nigeria.

Adewole OO, Erhabor GE, Sogaolu MO, Onipede AO, Owiafe PK, Awopeju FO, Ota MO.

West Afr J Med. 2013 Jul-Sep;32(3):180-5. English, French.

PMID:
24122682
38.

Immunogenic Mycobacterium africanum strains associated with ongoing transmission in The Gambia.

Gehre F, Antonio M, Otu JK, Sallah N, Secka O, Faal T, Owiafe P, Sutherland JS, Adetifa IM, Ota MO, Kampmann B, Corrah T, de Jong BC.

Emerg Infect Dis. 2013 Oct;19(10):1598-1604. doi: 10.3201/eid1910.121023.

39.

Skewing of the CD4(+) T-cell pool toward monofunctional antigen-specific responses in patients with immune reconstitution inflammatory syndrome in The Gambia.

Wilson H, de Jong BC, Peterson K, Jaye A, Kampmann B, Ota MO, Sutherland JS.

Clin Infect Dis. 2013 Aug;57(4):594-603. doi: 10.1093/cid/cit285. Epub 2013 May 3.

PMID:
23645847
40.

Impact, challenges, and future projections of vaccine trials in Africa.

Idoko OT, Kochhar S, Agbenyega TE, Ogutu B, Ota MO.

Am J Trop Med Hyg. 2013 Mar;88(3):414-9. doi: 10.4269/ajtmh.12-0576. Review.

41.

Interferon-γ ELISPOT as a biomarker of treatment efficacy in latent tuberculosis infection: a clinical trial.

Adetifa IM, Ota MO, Jeffries DJ, Lugos MD, Hammond AS, Battersby NJ, Owiafe PK, Donkor SD, Antonio M, Ibanga HB, Brookes RH, Aka P, Walton R, Adegbola RA, Hill PC.

Am J Respir Crit Care Med. 2013 Feb 15;187(4):439-45. doi: 10.1164/rccm.201208-1352OC. Epub 2012 Dec 6.

PMID:
23220919
42.

Pneumococcal antibody concentrations of subjects in communities fully or partially vaccinated with a seven-valent pneumococcal conjugate vaccine.

Ota MO, Roca A, Bottomley C, Hill PC, Egere U, Greenwood B, Adegbola RA.

PLoS One. 2012;7(8):e42997. doi: 10.1371/journal.pone.0042997. Epub 2012 Aug 14.

43.

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.

Odutola AA, Owolabi OA, Owiafe PK, McShane H, Ota MO.

Vaccine. 2012 Aug 17;30(38):5591-4. doi: 10.1016/j.vaccine.2012.06.054. Epub 2012 Jun 27.

PMID:
22749600
44.

Human immune responses to vaccines in the first year of life: biological, socio-economic and ethical issues - a viewpoint.

Ota MO, Idoko OT, Ogundare EO, Afolabi MO.

Vaccine. 2013 May 17;31(21):2483-8. doi: 10.1016/j.vaccine.2012.06.018. Epub 2012 Jun 19. Review.

PMID:
22728219
45.

Pneumococcal antibody concentrations and carriage of pneumococci more than 3 years after infant immunization with a pneumococcal conjugate vaccine.

Akinsola AK, Ota MO, Enwere GC, Okoko BJ, Zaman SM, Saaka M, Nsekpong ED, Odutola AA, Greenwood BM, Cutts FT, Adegbola RA.

PLoS One. 2012;7(2):e31050. doi: 10.1371/journal.pone.0031050. Epub 2012 Feb 20.

46.

Highly accurate diagnosis of pleural tuberculosis by immunological analysis of the pleural effusion.

Sutherland JS, Garba D, Fombah AE, Mendy-Gomez A, Mendy FS, Antonio M, Townend J, Ideh RC, Corrah T, Ota MO.

PLoS One. 2012;7(1):e30324. doi: 10.1371/journal.pone.0030324. Epub 2012 Jan 25.

47.

Identification of probable early-onset biomarkers for tuberculosis disease progression.

Sutherland JS, Hill PC, Adetifa IM, de Jong BC, Donkor S, Joosten SA, Opmeer L, Haks MC, Ottenhoff TH, Adegbola RA, Ota MO.

PLoS One. 2011;6(9):e25230. doi: 10.1371/journal.pone.0025230. Epub 2011 Sep 23.

48.

Identification of biomarkers for tuberculosis disease using a novel dual-color RT-MLPA assay.

Joosten SA, Goeman JJ, Sutherland JS, Opmeer L, de Boer KG, Jacobsen M, Kaufmann SH, Finos L, Magis-Escurra C, Ota MO, Ottenhoff TH, Haks MC.

Genes Immun. 2012 Jan;13(1):71-82. doi: 10.1038/gene.2011.64. Epub 2011 Sep 29.

PMID:
21956656
49.

Bacterial Isolates and Antibiotic Sensitivity among Gambian Children with Severe Acute Malnutrition.

Okomo UA, Garba D, Fombah AE, Secka O, Ikumapayi UN, Udo JJ, Ota MO.

Int J Pediatr. 2011;2011:825123. doi: 10.1155/2011/825123. Epub 2011 Jul 14.

50.

Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.

Ota MO, Odutola AA, Owiafe PK, Donkor S, Owolabi OA, Brittain NJ, Williams N, Rowland-Jones S, Hill AV, Adegbola RA, McShane H.

Sci Transl Med. 2011 Jun 22;3(88):88ra56. doi: 10.1126/scitranslmed.3002461.

Supplemental Content

Support Center